Ahmadieh, Hamid <br/><br/>
Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Oct 2011 
 - 1819-26 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e31820d58f2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Bevacizumab<br/>Drug Therapy, Combination<br/>Female<br/>Fluorescein Angiography<br/>Follow-Up Studies<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Retreatment<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Triamcinolone Acetonide--therapeutic use<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis